HAIM
ADAP

Hunter Associates Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Hunter Associates Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,000
Closed -$12K – 248
2024
Q4 		$12K Sell
22,000
-1,000
-4% -$729 ﹤0.01% 253
2024
Q3 		$22K Hold
23,000
– – ﹤0.01% 257
2024
Q2 		$22K Hold
23,000
– – ﹤0.01% 252
2024
Q1 		$37K Hold
23,000
– – 0.01% 257
2023
Q4 		$19K Sell
23,000
-1,000
-4% -$564 ﹤0.01% 257
2023
Q3 		$20K Sell
24,000
-1,500
-6% -$1.26K ﹤0.01% 249
2023
Q2 		$24K Hold
25,500
– – ﹤0.01% 248
2023
Q1 		$28K Sell
25,500
-1,500
-6% -$2.32K 0.01% 254
2022
Q4 		$38K Sell
27,000
-1,500
-5% -$2.43K 0.01% 227
2022
Q3 		$31K Hold
28,500
– – 0.01% 215
2022
Q2 		$49K Buy
28,500
+8,500
+43% +$14.6K 0.01% 218
2022
Q1 		$41K Buy
20,000
+9,000
+82% +$24.3K 0.01% 140
2021
Q4 		$41K Buy
+11,000
New +$50.1K 0.01% 151
2021
Q2 		– Sell
-15,825
Closed -$84K – 140
2021
Q1 		$84K Buy
+15,825
New +$90.6K 0.02% 201

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hunter Associates Investment Management's ADAP Position: Q1 2025 in Review

Hunter Associates Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 22,000 shares — an estimated $12K sold.

Hunter Associates Investment Management first reported a position in ADAP in Q1 2021 and held it in 14 quarters. The position peaked at $84K in Q1 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Hunter Associates Investment Management reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hunter Associates Investment Management sold 22,000 Adaptimmune Therapeutics shares in Q1 2025, an estimated $12K.
  • Hunter Associates Investment Management first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 14 quarters.
  • Hunter Associates Investment Management's Adaptimmune Therapeutics position peaked at $84K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Hunter Associates Investment Management's 13F filing for Q1 2025, filed 30 Apr 2025.